Qtorin rapamycin 3.9% anhydrous gel
Palvella Therapeutics (PVLA)
Decision dateFeb 28, 2027
105 days away
Marketer take
The company calls it potentially the first FDA-approved therapy for this condition and is building commercial and medical affairs teams ahead of the date.
- Sponsor company
- Palvella Therapeutics (PVLA)
- Indication
- Microcystic lymphatic malformations
- Therapeutic area
- Dermatology, Rare disease
- Event
- PDUFA target action date
- Date
- Feb 28, 2027
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?